Infant Mortality Reduction by the Mass Administration of Azithromycin

Phase 4 Active not recruiting 694400 enrolled University of California, San Francisco Bill and Melinda Gates Foundation · collab Centre de Recherche en Sante de Nouna, Burkina Faso · collab Helen Keller International · collab

RandomizedFactorialQuadruple-blindPrevention

Summary

This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.

Timeline

Start: 2021-10-04
Primary completion: 2025-01-30
Completion: 2026-01-30

Publications

Background Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM; MORDOR Study Group. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med. 2018 Apr 26;378(17):1583-1592. doi: 10.1056/NEJMoa1715474.
Yago-Wienne F, Toure D, Dimithe G, Khassanova R, Sidibe S, Some PN, Bamba I, Zombre V, Sie A, Bountogo M, Coulibaly B, Ouattara M, Peterson B, Arnold B, Lietman TM, Lebas E, O'Brien KS. Integration of azithromycin mass administration to 1-11-month-old children into an existing health platform to reduce child mortality: a cluster-randomised trial in Burkina Faso. BMJ Glob Health. 2026 Jan 8;11(1):e021336. doi: 10.1136/bmjgh-2025-021336.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Azithromycin	Small molecule	—	Oral

Indications

No indication recorded.